For hip fracture , at a 15 % relative risk , the effect estimate lay between the futility boundary and the inferior boundary , meaning there is reliable evidence that vitamin D supplementation does not reduce hip fractures by this amount , but uncertainty remains as to whether it might increase hip fractures .
The effect estimate lay within the futility boundary at thresholds of 0·5 % for total hip , forearm , and total body bone mineral density , and 1·0 % for lumbar spine and femoral neck , providing reliable evidence that vitamin D does not alter these outcomes by these amounts .
INTERPRETATION Our findings suggest that vitamin D supplementation does not prevent fractures or falls , or have clinical ly meaningful effects on bone mineral density .
There were no differences between the effects of higher and lower doses of vitamin D. There is little justification to use vitamin D supplements to maintain or improve musculoskeletal health .
BACKGROUND The effects of vitamin D on fractures , falls , and bone mineral density are uncertain , particularly for high vitamin D doses .
We aim ed to determine the effect of vitamin D supplementation on fractures , falls , and bone density .
Vitamin D and Physical Function in Sedentary Older Men
OBJECTIVES To determine the effectiveness of vitamin D supplementation in preventing decline in physical function in older men . DESIGN R and omized , double-blind , placebo-controlled clinical trial . SETTING Single-center study conducted at a Veterans Affairs Healthcare System . PARTICIPANTS Sedentary men aged 65 to 90 ( mean 72.4 ± 6.8 ) with baseline 25-hydroxyvitamin D ( 25(OH)D levels of less than 30 ng/mL and Short Physical Performance Battery ( SPPB ) test scores of 9 or less ( N = 130 ) . INTERVENTION Daily capsule containing cholecalciferol 4,000 IU daily or placebo for 9 months . MEASUREMENTS Main outcomes were SPPB score and gait speed . RESULTS After the intervention , serum 25(OH)D increased from 23.1 ± 5.0 ng/mL to 46.2 ± 12.7 ng/mL in the cholecalciferol group and from 22.5 ± 5.3 ng/mL to 24.0 ± 7.2 ng/mL in the placebo group . At study end , improvements in SPPB score and gait speed were not significantly greater in men receiving cholecalciferol than in those receiving placebo . No differences were found in adverse events or numbers of falls . CONCLUSION Daily cholecalciferol 4,000 IU for 9 months result ed in significant increases in 25(OH)D concentrations , but achieving these higher levels did not result in improvements in SPPB score or gait speed . These data do not support prescribing vitamin D supplements to older sedentary men to prevent physical function decline
For hip fracture , at a 15 % relative risk , the effect estimate lay between the futility boundary and the inferior boundary , meaning there is reliable evidence that vitamin D supplementation does not reduce hip fractures by this amount , but uncertainty remains as to whether it might increase hip fractures .
The effect estimate lay within the futility boundary at thresholds of 0·5 % for total hip , forearm , and total body bone mineral density , and 1·0 % for lumbar spine and femoral neck , providing reliable evidence that vitamin D does not alter these outcomes by these amounts .
INTERPRETATION Our findings suggest that vitamin D supplementation does not prevent fractures or falls , or have clinical ly meaningful effects on bone mineral density .
There were no differences between the effects of higher and lower doses of vitamin D. There is little justification to use vitamin D supplements to maintain or improve musculoskeletal health .
BACKGROUND The effects of vitamin D on fractures , falls , and bone mineral density are uncertain , particularly for high vitamin D doses .
We aim ed to determine the effect of vitamin D supplementation on fractures , falls , and bone density .